Exploring coding and signal joints of novel TCR beta D-D rearrangements for tracking T-cell leukemia clonality Authors: A. M. Miroshnichenkova, V. K. Ruppel, A. O. Smirnova, A. Borkovskaia, B. E. Minasian, A. V. Pavlova, P. V. Shelyakin, A. N. Kazakova, E. A. Zerkalenkova, A. I. Karachunsky, M. A. Maschan, Y. Ventura-Carmenate, D. M. Chudakov, Y. V. Olshanskaya, A. Y. Komkov Published: 2025 ABSTRACT Rearranged T and B-cell receptor loci serve as critical clonal markers for studying adaptive immune system functioning during normal immune response and abnormal expansion in lymphoid malignancies. Analyses of both complete and partial TCR/BCR gene rearrangements provide valuable insights into the clonal proliferation of malignant T and B lymphocytes. Our earlier work identified novel partial rearrangements between two D (diversity) genes in the human TRB locus in normal T cells from peripheral blood and thymus. In this study, we demonstrate the presence of these novel rearrangements in leukemic T cells, explore their properties for clonality assessment and potential use in minimal residual disease (MRD) monitoring in acute lymphoblastic leukemia, and lay the foundation for further clinical validation.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40164-025-00730-8. To the editor The identification and tracking of clonal T-cell populations are critical for understanding disease dynamics and guiding treatment strategies in T-cell acute lymphoblastic leukemia (T-ALL) [1–3]. The classical partial and complete T-cell receptor rearrangements (TRD, TRG, TRB, and TRA loci) have long served as the foundation for clonality assessment and minimal residual disease (MRD) monitoring [4–7]. However, the insufficient specificity and potential instability of some of these markers during clonal evolution highlight the need for assays that incorporate multiple markers to ensure robust detection and minimize false results. In this study, we introduce and characterize a new category of genomic events: short and long TRB D-D rearrangements, generated through conventional VDJ recombination (Fig. 1A–C). The short TRB D-D rearrangements represent chromosomal signal joints lacking coding D-genes, while the long variants are coding joints with two linked D-genes. Here, we report the occurrence of such TRB D-D rearrangements in leukemic cells, highlighting their potential application for clonality assessment and MRD analysis for T-ALL patients.Fig. 1TRB D-D rearrangements identification. A Scheme of TRBD1-TRBD2 recombination. B Scheme of sequencing library preparation. C Identification of TRB D-D signal and coding joints excised from the chromosome during TRBD1-TRBD2 recombination. D Cumulative distribution of sizes of first “not-empty” TRB D-D clonotypes across normal samples for selection of clonotype size threshold. E Sizes of top 20 TRB D-D clonotypes (excluding “empty” one) in leukemic and normal repertoires. TREC—T-cell receptor excision circle, UDP—Unique Dual Indexing Primers, HD—healthy donor, P—patient, for—forward, rev—reverse TRB D-D rearrangements identification. A Scheme of TRBD1-TRBD2 recombination. B Scheme of sequencing library preparation. C Identification of TRB D-D signal and coding joints excised from the chromosome during TRBD1-TRBD2 recombination. D Cumulative distribution of sizes of first “not-empty” TRB D-D clonotypes across normal samples for selection of clonotype size threshold. E Sizes of top 20 TRB D-D clonotypes (excluding “empty” one) in leukemic and normal repertoires. TREC—T-cell receptor excision circle, UDP—Unique Dual Indexing Primers, HD—healthy donor, P—patient, for—forward, rev—reverse Using our targeted sequencing approach (Fig. 1B) we confirm that TRB D-D rearrangements, initially described in normal T cells [8], also occur in leukemic clones, dominating over normal T cell background (Fig. 1D, E). In our cohort of 223 T-ALL patients (T-II, T-III and T-IV subtypes), 79% of samples harbored 1–4 TRB D-D clonotypes with clone sizes > 10%, and 30% of cases contained TRB D-D clonotypes with sizes over 50% (Fig. 2A), underscoring their prevalence and relevance in T-ALL. Structurally, leukemia-related TRB D-D clonotypes were indistinguishable from those found in normal T cells (Fig. 2B). A key difference lies in the composition of top-ranking clonotypes: in normal T cells, the dominant TRB D-D clonotype is an “empty” signal joint without N-additions occupying 20–42% of the repertoire (Fig. 2C), with the second-ranking clonotype rarely exceeding 10% even in older people (Fig. 1D), who tend to accumulate larger T-cell clones with age. In contrast, T-ALL samples exhibit a broader distribution of “empty” clonotype sizes (5–100%) without consistent dominance across samples (Fig. 2C). Notably, 67% of T-ALL have other more diverse clonal TRB D-D rearrangements in the top-ranked position.Fig. 2Structural and quantitative features of TRB D-D rearrangements in T-ALL. A Randomly selected examples of dominant TRB D-D clonotypes in T-ALL samples. B Comparison of TRB D-D clonotypes in normal and leukemic samples. The TRB D-D junction length was calculated, excluding recombination signals (RSS). C Clone size comparison of short TRB D-D clonotypes without non-templated insertions (“empty” TRB D-D) in normal and T-ALL samples. D Generation probability of TRB D-D signal and coding joints. Curves represent density of generation probabilities of TRB D-D from normal samples. Solid vertical lines represent leukemia-related TRB D-D rearrangements. Red dashed vertical lines represent established marker selection threshold. E Comparison of N-additions lengths between shared and unique clonotypes. Mann–Whitney two-tailed test, black bars represent medians. F Correlation of specificity with generation probability and N-additions for leukemia-related TRB D-D signal and coding joints. G Dynamics of leukemia-related TBD D-D clonotypes between T-ALL onset and relapse. RP—relapsed patient. Each nucleotide sequence represents a separately generated TRB D-D clonotype. TRB D-D junctions shown without RSS Structural and quantitative features of TRB D-D rearrangements in T-ALL. A Randomly selected examples of dominant TRB D-D clonotypes in T-ALL samples. B Comparison of TRB D-D clonotypes in normal and leukemic samples. The TRB D-D junction length was calculated, excluding recombination signals (RSS). C Clone size comparison of short TRB D-D clonotypes without non-templated insertions (“empty” TRB D-D) in normal and T-ALL samples. D Generation probability of TRB D-D signal and coding joints. Curves represent density of generation probabilities of TRB D-D from normal samples. Solid vertical lines represent leukemia-related TRB D-D rearrangements. Red dashed vertical lines represent established marker selection threshold. E Comparison of N-additions lengths between shared and unique clonotypes. Mann–Whitney two-tailed test, black bars represent medians. F Correlation of specificity with generation probability and N-additions for leukemia-related TRB D-D signal and coding joints. G Dynamics of leukemia-related TBD D-D clonotypes between T-ALL onset and relapse. RP—relapsed patient. Each nucleotide sequence represents a separately generated TRB D-D clonotype. TRB D-D junctions shown without RSS An essential consideration in MRD applications is the reliability of clonal markers [9], specifically their low generation probability (Pgen), ensuring they are absent in patient’s normal cells or donor graft. Using 102 normal TRB D-D repertoires we inferred Pgen model [10] to calculate TRB D-D generation probability (Fig. 2D) and establish threshold for unique clonotypes selection. Additionally, we detected minimal number of four N-additions distinguishing shared and unique TRB D-D clonotypes (Fig. 2E). Using Pgen > 10–5 and four N-additions as thresholds for leukemic TRB D-D markers selection the specificity of > 94% can be achieved (Fig. 2F) reliably distinguishing shared and unique clonotypes. After excluding shared clonotypes, 133 (60% of total cohort) T-ALL samples retained at least one unique TRB D-D clonotype and thus potentially qualified for MRD assessment with TRB D-D markers. Another clinically relevant observation is the persistence of TRB D-D clonotypes across disease timepoints. In 89% of T-ALL cases that contained unique clonotypes at diagnosis, the same clonotypes remained identifiable at relapse (52% of analysed pairs) (Fig. 2G), underscoring their proximity to classical TR markers stability [11] throughout clonal evolution and under therapeutic pressure, supporting their usability in long-term clonal tracking. Despite their promise, TRB D-D rearrangements cannot fully replace classical TR markers. In 30% of T-ALL cases, they were absent while traditional markers (TRD, TRG, TRB, and TRA) were present, though 40% of the latter were not unique (Supplementary). Therefore, the role of TRB D-D should be considered as complementary markers, particularly beneficial in increasing marker multiplicity to enhance robustness of clonality assessment and reduce false results in MRD monitoring. In conclusion, our findings expand the landscape of TR-based clonal markers in T-ALL and highlight the translational value of TRB D-D rearrangements for improving leukemia monitoring. Detection of TRB D-D rearrangements requires only two PCR primers, preventing multiplex PCR-driven quantitative bias compared to most other TR rearrangements [12] and facilitating incorporation in existing NGS-based systems for clonality assessment [13]. However, implementation in clinical practice requires a large multicentre study exploring the applicability of TRB D-D markers across diverse T-cell malignancies, their potential integration into standardized clinical MRD assays, and extensive clinical validation. Supplementary Information Additional file1 (PDF 1393 kb) Additional file1 (PDF 1393 kb)